Login to Your Account



Genelabs' Stock Skyrockets On Lupus Drug Approvable Letter

By Randall Osborne


Tuesday, September 3, 2002
On the brink of the Labor Day holiday, Genelabs Technologies Inc. saw gratifying results from the sometimes-uphill labor on behalf of its lupus drug, Prestara (prasterone), as the company's stock more than doubled on news of an approvable letter from the FDA. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription